150O Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
D.S. Hong
◽
A. Dowlati
◽
H.A. Burris
◽
J.J. Lee
◽
M.S. Brose
◽
...
2016 ◽
Vol 27
(suppl_9)
◽
D.S. Hong
◽
A. Dowlati
◽
H.A. Burris
◽
J.J. Lee
◽
M.S. Brose
◽
...
David S. Hong
◽
Marcia S. Brose
◽
Robert C. Doebele
◽
Alice T. Shaw
◽
Afshin Dowlati
◽
...
2017 ◽
Vol 72
◽
pp. S148
◽
D.S. Hong
◽
A. Dowlati
◽
H.A. Burris
◽
J.J. Lee
◽
M.S. Brose
◽
...
2019 ◽
Vol 111
(2)
◽
pp. 536-547
◽
Yung‐Jue Bang
◽
Wu‐Chou Su
◽
Martin Schuler
◽
Do‐Hyun Nam
◽
Wan Teck Lim
◽
...
David S. Hong
◽
Anna F. Farago
◽
Marcia S. Brose
◽
Howard A. Burris
◽
Afshin Dowlati
◽
...
2015 ◽
Vol 4
(10)
◽
pp. 1472-1483
◽
Talia Golan
◽
Tal Grenader
◽
Patricia Ohana
◽
Yasmine Amitay
◽
Hilary Shmeeda
◽
...
Marie O'Farrell
◽
Richard Crowley
◽
Timothy Heuer
◽
Marina Fridlib
◽
Doug Buckley
◽
...
Marie O'Farrell
◽
Richard Crowley
◽
Timothy S. Heuer
◽
Doug Buckley
◽
Chris M. Rubino
◽
...
Nuhad Ibrahim
◽
Lucas Wong
◽
Alison Stopeck
◽
Lee S. Rosen
◽
David E. Gerber
◽
...
2006 ◽
Vol 12
(12)
◽
pp. 3782-3791
◽
Larry J. Schaaf
◽
Lisa A. Hammond
◽
Stuart J. Tipping
◽
Richard M. Goldberg
◽
Rakesh Goel
◽
...